Analysts Have Conflicting Sentiments on These Healthcare Companies: Deciphera Pharmaceuticals (DCPH), Atara Biotherapeutics (ATRA) and Nkarta (NKTX)

TipRanksMay 16 10:10

EnGene Holdings: Nkarta's Paul Hastings and Forbion's Wouter Joustra Elected to Bd >ENGN

EnGene Holdings: Nkarta's Paul Hastings and Forbion's Wouter Joustra Elected to Bd >ENGN

Dow JonesMay 16 04:17

Nkarta Price Target Raised to $23.00/Share From $22.00 by HC Wainwright & Co.

Nkarta Price Target Raised to $23.00/Share From $22.00 by HC Wainwright & Co.

Dow JonesMay 14 01:56

Nkarta Is Maintained at Buy by Needham

Nkarta Is Maintained at Buy by Needham

Dow JonesMay 14 01:44

Needham: Maintaining the Nkarta (NKTX.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $15.00 to $13.00.

Needham: Maintaining the Nkarta (NKTX.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $15.00 to $13.00.

Zhitong FinanceMay 14 01:40

Needham Maintains Buy on Nkarta, Lowers Price Target to $13

Needham analyst Gil Blum maintains Nkarta with a Buy and lowers the price target from $15 to $13.

Analyst UpgradesMay 14 01:33